Truqap Proves False For AstraZeneca
The company’s attempt to move the AKT inhibitor into first-line triple-negative breast cancer proves a dud with the failure of the CAPItello-290 Phase III trial.
The company’s attempt to move the AKT inhibitor into first-line triple-negative breast cancer proves a dud with the failure of the CAPItello-290 Phase III trial.